

Neuroinflammation in fibromyalgia and CRPS is multifactorial

Littlejohn¹ ascribes neuroinflammation to a “neurogenic” origin, presumably triggered by pain and stress. However, attribution of neuroinflammation and central sensitization to a primary neurogenic origin is premature without integrating the well-documented coexistence of small intestine bacterial overgrowth (SIBO, one type of gastrointestinal dysbiosis), vitamin D deficiency, and mitochondrial dysfunction.

Littlejohn¹ notes that “chronic pain was more strongly associated with lipopolysaccharide–stimulated proinflammatory cytokines”; however, he does not pursue this line of thought to connect it to relevant literature showing clear evidence of gastrointestinal dysbiosis and increased intestinal permeability in patients with fibromyalgia (FM) and complex regional pain syndrome (CRPS). The gastrointestinal tract is the most abundant source of lipopolysaccharide (LPS, endotoxin), systemic absorption of which is increased by SIBO and increased intestinal permeability. In 1999, Pimentel et al² showed that oral administration of antibiotics lead to alleviation of pain and other clinical measures of FM. In 2004, Pimentel et al³ showed that among 42 fibromyalgia patients, all 42 FM patients (100%) showed laboratory evidence of SIBO, severity of which correlated positively with severity of FM. In that same year, Wallace and Hallegua⁴ showed that eradication of SIBO with antimicrobial therapy lead to clinical improvements in FM patients in direct proportion to antimicrobial efficacy. In 2008, Goebel et al⁵ documented that patients with FM and CRPS have intestinal hyperpermeability; mucosal “leakiness” was highest in patients with CRPS, indicating a strong gastrointestinal component to the illness. In 2013, Reichenberger et al⁶ showed that CRPS patients have a distinct alteration in their gastrointestinal microbiome characterized by reduced diversity and significantly increased levels of *Proteobacteria*. LPS from Gram-negative bacteria is powerfully pro-inflammatory and is known to trigger microglial activation via Toll-like receptor 4; experimental studies have shown that LPS promotes muscle mitochondrial impairment, peripheral hyperalgesia, and central sensitization.

Vitamin D deficiency is prevalent in chronic pain patients and promotes pain sensitization⁷, systemic inflammation, intestinal hyperpermeability, myalgia and bone pain (osteomalacia). Human clinical trials have shown that vitamin D supplementation can alleviate inflammation⁸, intestinal hyperpermeability⁹, FM pain¹⁰ and other neuromusculoskeletal pain. Vitamin D reduces experimental microglial activation¹¹, a component of neuroinflammation and central sensitization.

Mitochondrial dysfunction in FM¹² and CRPS¹³ can be triggered by gastrointestinal dysbiosis via LPS, D-lactate, and hydrogen sulfide; mitochondrial dysfunction exacerbates and perpetuates microglial activation and glutaminergic neurotransmission¹⁴ and thereby promotes pain sensitization centrally while also contributing to muscle pain peripherally.¹⁵ Treatment of mitochondrial dysfunction with ubiquinone alleviates biochemical and clinical manifestations of FM.¹²

Thus, neuroinflammation in FM and CRPS has biological contributions, including but not limited to gastrointestinal dysbiosis, vitamin D deficiency, and mitochondrial dysfunction. These independent contributions commonly coexist in FM and CRPS patients, and each of these is additive/synergistic with the others in the promotion of peripheral and central hyperalgesia. Neuroinflammation likely has a neurogenic component¹, but the consistent pain-alleviating benefits of treatments for intestinal dysbiosis (antibiotics), vitamin D deficiency (supplementation) and mitochondrial dysfunction (ubiquinone) establish that these painful conditions are multifactorial and maintained by ongoing physiologic insults, each of which is treatable.

Alex Vasquez DC ND DO FACN

International College of Human Nutrition and Functional Medicine ICHNFM.ORG Barcelona Spain 08001

Competing interests: Dr Vasquez has lectured for Biotics Research Corporation, a nutraceutical company in the USA.

Original title: Neuroinflammation and Central Sensitization in Fibromyalgia and Complex Regional Pain Syndrome: Synergy of Glial Inflammation, Mitochondrial Dysfunction, Gut Dysbiosis (Microbiome Imbalance) and Vitamin D Deficiency

Published title: Neuroinflammation in fibromyalgia and CRPS is multifactorial

Journal: *Nature Reviews Rheumatology*

Citation: Vasquez A. Neuroinflammation in fibromyalgia and CRPS is multifactorial. *Nat Rev Rheumatol.* 2016 Apr;12(4):242

Hyperlink: <http://www.nature.com/nrrheum/journal/v12/n4/full/nrrheum.2016.25.html>

DOI: 10.1038/nrrheum.2016.25

PMID: 26935282

1. Littlejohn G. Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome. *Nat Rev Rheumatol.* 2015 Nov;11(11):639-48
2. Pimentel M, Hallegua DS, Wallace DJ, et al. Improvement of symptoms by eradication of small intestinal overgrowth in FMS: a double-blind study [abstract]. *Arthritis Rheum* 1999, 42:S343
3. Pimentel et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. *Ann Rheum Dis.* 2004 Apr;63(4):450-2
4. Wallace DJ, Hallegua DS. Fibromyalgia: the gastrointestinal link. *Curr Pain Headache Rep.* 2004 Oct;8(5):364-8
5. Goebel et al. Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. *Rheumatology* 2008 Aug;47(8):1223-7
6. Reichenberger et al. Establishing a relationship between bacteria in the human gut and complex regional pain syndrome. *Brain Behav Immun.* 2013 Mar;29:62-9
7. von Känel R, Müller-Hartmannsgruber V, Kokkinos G, Egloff N. Vitamin D and central hypersensitivity in patients with chronic pain. *Pain Med.* 2014 Sep;15(9):1609-18
8. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? *QJM.* 2002 Dec;95(12):787-96
9. Raftery T, Martineau AR, Greiller CL, Ghosh S, McNamara D, Bennett K, Meddings J, O'Sullivan M. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study. *United European Gastroenterol J.* 2015 Jun;3(3):294-302
10. Wepner F, Scheuer R, Schuetz-Wieser B, Machacek P, Pieler-Bruha E, Cross HS, Hahne J2, Friedrich M. Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial. *Pain.* 2014 Feb;155(2):261-8
11. Hur J, Lee P, Kim MJ, Cho YW. Regulatory Effect of 25-hydroxyvitamin D3 on Nitric Oxide Production in Activated Microglia. *Korean J Physiol Pharmacol.* 2014 Oct;18(5):397-402
12. Cordero MD, Cano-García FJ, Alcocer-Gómez E, De Miguel M, Sánchez-Alcázar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q10 effect on clinical improvement. *PLoS One.* 2012;7(4):e35677
13. Tan EC, Janssen AJ, Roestenberg P, van den Heuvel LP, Goris RJ, Rodenburg RJ. Mitochondrial dysfunction in muscle tissue of complex regional pain syndrome type I patients. *Eur J Pain.* 2011 Aug;15(7):708-15
14. Nguyen D, Alavi MV, Kim KY, Kang T, Scott RT, Noh YH, Lindsey JD, Wissinger B, Ellisman MH, Weinreb RN, Perkins GA, Ju WK. A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. *Cell Death Dis.* 2011 Dec 8;2:e240
15. Vasquez A. *Human Microbiome and Dysbiosis in Clinical Disease.* (International College of Human Nutrition and Functional Medicine; Barcelona, 2015) ISBN 0990620417


INFLAMMATION MASTERY

4TH EDITION

CLINICAL NUTRITION, FUNCTIONAL MEDICINE, MITOCHONDRIAL DYSFUNCTION, MICROBIOME & DYSBIOSIS, FUNCTIONAL INFLAMMOLOGY, PAIN MANAGEMENT, INTEGRATIVE RHEUMATOLOGY, NUTRITIONAL IMMUNOMODULATION, IMMUNONUTRITION & ANTIVIRAL STRATEGIES

The Colorful and Definitive Guide Toward Health and Vitality
and away from the Boredom, Risks, Costs, and Inefficacy of
Endless Analgesia, Immunosuppression, and Polypharmacy

3-Part Learning System of Text, Illustrations, and Video



DR. ALEX VASQUEZ

ICHNFM.ORG

INTERNATIONAL COLLEGE OF HUMAN NUTRITION AND FUNCTIONAL MEDICINE

INFLAMMATION MASTERY

**4TH EDITION: THE COLORFUL AND DEFINITIVE GUIDE
TOWARD HEALTH AND VITALITY AND AWAY FROM THE
BOREDOM, RISKS, COSTS, AND INEFFICACY OF ENDLESS
ANALGESIA, IMMUNOSUPPRESSION, AND POLYPHARMACY**

A Three-Part Learning System of Text, Images, and Video

ALEX VASQUEZ D.C. N.D. D.O. F.A.C.N.

- ♦ Doctor of Osteopathic Medicine, graduate of University of North Texas Health Science Center, Texas College of Osteopathic Medicine (2010)
- ♦ Doctor of Naturopathic Medicine, graduate of Bastyr University (1999)
- ♦ Doctor of Chiropractic, graduate of University of Western States (1996)
- ♦ Fellow of the American College of Nutrition (2013-present)
- ♦ Former Overseas Fellow of the Royal Society of Medicine
- ♦ Editor, *International Journal of Human Nutrition and Functional Medicine* IntJHumNutrFunctMed.org. Former Editor, *Naturopathy Digest*; Former/Recent Reviewer for *Journal of Naturopathic Medicine*, *Alternative Therapies in Health and Medicine*, *Autoimmune Diseases*, *International Journal of Clinical Medicine*, and *PLOS One*
- ♦ Private practice of integrative and functional medicine in Seattle, Washington (2000-2001), Houston, Texas (2001-2006), Portland, Oregon (2011-2013), consulting practice (present)
- ♦ Consultant Researcher and Lecturer (2004-present), Biotics Research Corporation
- ♦ Teaching and Academics:
 - Director of Programs, International College/Conference on Human Nutrition and Functional Medicine ICHNFM.org
 - Founder and Former Program Director of the world's first accredited university-affiliated graduate-level program in Functional Medicine
 - Adjunct Professor, Integrative and Functional Nutrition in Immune Health, Doctor of Clinical Nutrition program at Maryland University of Integrative Health
 - Former Adjunct Professor (2009-2013) of Laboratory Medicine, Master of Science in Advanced Clinical Practice
 - Former Faculty (2004-2005, 2010-2013) and Forum Consultant (2003-2007), The Institute for Functional Medicine
 - Former Adjunct Professor (2011-2013) of Pharmacology, Evidence-Based Nutrition, Immune and Inflammatory Imbalances, Principles of Functional Medicine, Psychology of Wellness
 - Former Adjunct Professor of Orthopedics (2000), Radiographic Interpretation (2000), and Rheumatology (2001), Naturopathic Medicine Program, Bastyr University
- ♦ Author of more than 100 articles and letters published in *JAMA—Journal of the American Medical Association*, *BMJ—British Medical Journal*, TheLancet.com, *JAOA—Journal of the American Osteopathic Association*, *Annals of Pharmacotherapy*, *Journal of Clinical Endocrinology and Metabolism*, *Alternative Therapies in Health and Medicine*, *Nutritional Perspectives*, *Journal of Manipulative and Physiological Therapeutics*, *Integrative Medicine*, *Current Allergy and Asthma Reports*, *Nutritional Wellness*, *Evidence-based Complementary and Alternative Medicine*, and *Arthritis & Rheumatism*: Official Journal of the American College of Rheumatology

INTERNATIONAL COLLEGE OF HUMAN NUTRITION & FUNCTIONAL MEDICINE
ICHNFM.ORG

BOOK OF CLINICAL NUTRITION & FUNCTIONAL MEDICINE

VOLUME 1: ESSENTIAL KNOWLEDGE FOR SAFE ACTION AND EFFECTIVE THERAPY

Alex Vasquez • ICHNFM.ORG

TEXTBOOK OF CLINICAL NUTRITION & FUNCTIONAL MEDICINE

VOLUME 2: PROTOCOLS FOR COMMON INFLAMMATORY DISORDERS

Dr Alex Vasquez • ICHNFM.ORG

INFLAMMATION MASTERY 4TH ED.

Integrative Pain Management


Chapter 3: Concepts and Therapeutics in (Nondrug) Musculoskeletal Care and Integrative Pain Management

Persistent inadequacies in nutrition education/training among physicians

Introduction: Despite the acknowledged importance of diet in the prevention of obesity, diabetes, hypertension, and other components of cardiometabolic syndrome/disease, physicians are consistently and systematically untrained in nutrition. A few exemplary citations are summarized per the following: "What do resident physicians know about nutrition? (J Am Coll Nutr 2008 Apr²⁹): "OBJECTIVE:

Excerpt copyright © by Dr Alex Vasquez and International College of Human Nutrition and Functional Medicine ICHNFM.ORG. From *Inflammation Mastery 4th Edition*, also printed as a two-volume set as *Textbook of Clinical Nutrition and Functional Medicine*. All rights reserved and enforced internationally. See ICHNFM.ORG for details, videos, discounts.

the resultant changes in neurotransmission that lead to pain sensitivity and changes in behavior." In this work, I show that fibromyalgia is a unique combination of dysbiosis, mitochondrial impairment; both of these components need to be treated effectively to alleviate the brain inflammation—unique—in fibromyalgia. "Glial activation within the brain is different from and worse than glial activation or mitochondrial impairment by itself; it exacerbates both while also causing a vicious cycle that promotes emotional/psychiatric changes.



Microglial LPS reception leads to (extracellular) ATP elaboration, which stimulates astrocytes, which increases glutamatergic neurotransmission. Upon LPS stimulation, microglia rapidly release ATP, which binds to P2Y1 receptors on astrocytes, leading to increased glutamate release and subsequent neuronal activation. Front Cell Neurosci. 2013 Mar 28;7:32.

Verified in animal models and likely contributory to clinical pain syndromes such as fibromyalgia, bacterial endotoxin/LPS can also contribute to central sensitization. This concept is further substantiated in a following section on clinical pain syndromes and more so specific to fibromyalgia³⁶⁰ or general rheumatology.³⁶¹ The basic pathophysiology depicted below and itemized with citations thereafter.

Bacterial LPS → microglial activation → astrocyte hyperglutaminogenesis → neuronal

³⁶⁰ Béchade C, Cesselin B, Y. Bessis A. Microglial control of neuronal activity. *Front Cell Neurosci*. 2013 Mar 28;7:32. doi: 10.3389/fnec.2013.00032. ³⁶¹ Béchade C, Cesselin B, Y. Bessis A. Microglial control of neuronal activity. *Front Cell Neurosci*. 2013 Mar 28;7:32. doi: 10.3389/fnec.2013.00032.

Chapter 5.1—Functional Inflammation Protocol for Metabolic Inflammation: Migraine & Fibromyalgia





Illustration of the NMDA-type glutamate receptor, its activation effects, and nutritional modulation. The NMDA receptor is activated by glutamate, QUIN, and other substances which act as agonists (e.g., homocysteine or co-agonists (e.g., glycine)). Different forms of the NMDA receptor exist; thus, the image presented here is a generalized version that is conceptually accurate (rather than all-inclusive; for more details see reviews³⁷¹) and clinically relevant. Neuroexcitatory glutamate is converted to glutamate levels. Magnesium and zinc (and perhaps copper) retard the passage of calcium through this channel, thereby mitigating some of the effects of NMDA activation. Quenching nitric oxide (for example with hydrocortisone), which would otherwise trigger glutamate release, and dousing glial activation are important considerations not included in this illustration. For updates and additional information and explanations, see videos and articles at www.inflammationmastery.com

³⁷¹ Wyllie et al. Structure, function, and pharmacology of NMDA receptor channels. *Physiol Rev*. 2014;94:Suppl 1:S291-303. ³⁷² Wyllie et al. Structure, function, and pharmacology of NMDA receptor channels. *Physiol Rev*. 2014;94:Suppl 1:S291-303.


Chapter and Introduction	Page
Preamble	i
1. <u>Patient Assessments, Laboratory Interpretation, Clinical Concepts, Patient Management, Practice Management and Risk Reduction:</u> <i>This chapter introduces/reviews/updates patient assessments, laboratory interpretation, musculoskeletal emergencies, healthcare paradigms; the common and important conditions hemochromatosis and hypothyroidism are also included in this chapter since these need to be considered on a frequent basis in clinical practice</i>	1
2. <u>Wellness Promotion & Re-Establishing the Foundation for Health:</u> <i>Reviewed here are diet, lifestyle, psychosocial health, and — given the pervasiveness of persistent organic pollutants and their increasingly recognized clinical importance — an introduction to environmental medicine</i>	187
3. <u>Basic Concepts and Therapeutics in (Nondrug) Musculoskeletal Care and Integrative Pain Management:</u> <i>Nonpharmacologic management of musculoskeletal problems is preferred over pharmacologic (e.g., NSAID, Coxib, steroid, opioid) management because of the collateral benefits, safety, and cost-effectiveness associated with manual, dietary, botanical, and nutritional treatments. A brief discussion of the current crisis in musculoskeletal medicine is provided for contextualization and emphasis of the importance of expanding clinicians' knowledge of effective nondrug treatments</i>	243
4. <u>The Major Modifiable Factors in Sustained Inflammation:</u> <i>Major components of the "Functional Inflammation Protocol" are reviewed here, from concepts and molecular biology to an emphasis on practical clinical applications</i>	303
1) Food & Basic Nutrition	307
2) Infections: Dysbiosis / Viral	396 / 540
3) Nutritional Immunomodulation	609
4) Dysmetabolism, Mitochondrial Dysfunction, ERS/UPR, mTOR	622
5) Special Considerations: Sleep, Sociopsychology, Stress, Surgery	674
6) Endocrine Imbalances	688
7) Xenobiotic Immunotoxicity	699
5. <u>Clinical Applications</u>	713
1) Hypertension	727
2) Diabetes Mellitus	819
3) Migraine & Headaches	863
4) Fibromyalgia	901
5) Allergic Inflammation	984
6) Rheumatoid Arthritis	1019
7) Psoriasis and Psoriatic Arthritis	1038
8) Systemic Lupus Erythematosus	1053
9) Scleroderma & Systemic Sclerosis	1074
10) Vasculitic Diseases	1094
11) Spondyloarthropathies & Reactive Arthritis	1108
12) Sjögren Syndrome/Disease	1119
13) Raynaud's Syndrome/Phenomenon/Disorder	1127
14) Clinical Notes on Additional Conditions: Behçet's Disease, Sarcoidosis, Dermatomyositis and Polymyositis	1131
Index & Appendix	1154



Pictured above—Personal inscription from Dr. Jeffrey Bland at a book signing event for his book *Disease*

Delusion: My inclusion of Dr Bland's personal note above is not meant to imply that he is endorsing this book; he might very well reject any or all of it. Further, this inclusion does not imply that he carries those same sentiments beyond the day that he wrote them to me in May of 2014. Rather, my inclusion signifies our mutual respect as colleagues, and my personal respect for his thought and demeanor, and his influence on my life and work. I have respectfully honored him in this book as the founder of what most clinicians in America know as Functional Medicine, and I have developed and extended my own version of his concept—that disease states are malleable rather than destined—to the clinical management of inflammatory disorders under the name of Functional Inflammalogy. Importantly and personally—but not paradoxically if one understands the true goals of mentorship, affiliation, and friendship—due to the support of friends and colleagues, this book also represents a departure from concern that I had for endorsement from or agreement with other people, professions, universities, or organizations. In this book, I have presented the truth as I see it—without apology—and without any filtering other than as the limitations imposed by time, space, my own abilities, and limitations imposed by human physiology. This work—now published as *Inflammation Mastery, 4th Edition*—has been "in progress" since its origin as course notes for Orthopedics and Rheumatology which I taught at Bastyr University in Seattle in 2000-2001 and through its previous publications in many books starting with *Integrative Orthopedics* (2004) and *Integrative Rheumatology* (2006) and peer-reviewed articles in journals ranging from *Annals of Pharmacotherapy* to *Alternative Therapies in Health and Medicine*. In addition to spanning more than 16 years, this work has also spanned various countries and cultures—including Houston, Fort Worth, Austin (Texas), Seattle (Washington), Portland (Oregon) in the United States, then to Bogota, Colombia and Barcelona, Spain. I consider this volume to be my highest presentation of truth, accuracy, and clinical application that I could humanly muster while maintaining my own health, relationship, and other obligations. I will always remain open to correction and the updating of this work as the weight of evidence indicates. The goals of healthcare should be the optimization of physical health and psychosocial-intellectual freedom.

- Burning pain
- Dull ache
- Muscle weakness



BACK OF BODY

Below, indicate which pain/discomfort you are referring to and then quantify it by placing an "X" on

if pain: _____

Worst pain imaginable

ain: _____

Worst pain imaginable	
-----------------------	--

Review of Systems—checklist: Patients/clients are asked to provide more information by the arrow "→", also at the bottom of each page, and/or wherever more detail is warranted. This form can be completed by the clinician and/or by the client.

GENERAL HEALTH	Very rare-None	Occasional-Mild	Intermittent-Moderate	Frequent-Severe
Fatigue, lack of energy, lack of stamina	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Need to decrease or alter activities of daily living due to fatigue, pain, or illness	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Insomnia, lack of sleep	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Excessive tiredness and increased need for sleep	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Tired and/or not hungry after waking	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Pain at night, night sweats	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Enlarged lymph nodes	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Frequent infections	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Undesired weight loss	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Undesired weight gain, difficulty losing weight	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Cold hands or feet	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Compulsive/binge eating, increased appetite	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Decreased appetite	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Hypoglycemia, low blood sugar	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Allergies to food or environment	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Sensitivity to fumes, chemicals, odors, exhaust	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Have you been tested for iron disorders?	<input type="checkbox"/> NO	<input type="checkbox"/> YES	<input type="checkbox"/> ?	
Past diagnosis of serious illness or chronic health condition such a systemic disease, cancer, HIV, mental condition, heart disease, infection, kidney problems, or other condition	<input type="checkbox"/> NO	<input type="checkbox"/> YES→		
MUSCLES and JOINTS	Very rare-None	Occasional-Mild	Intermittent-Moderate	Frequent-Severe
Pain, swelling, or limited motion in joint(s)	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Pain, swelling, or weakness in muscle(s)	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Cramps in muscles, grind teeth at night?	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Other problem, concerns, or questions in this area?	<input type="checkbox"/> NO	<input type="checkbox"/> YES→		
HEAD and MIND	Very rare-None	Occasional-Mild	Intermittent-Moderate	Frequent-Severe
Headaches	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Feeling of pressure inside head	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Faintness, loss of consciousness	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Dizziness	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Seizures, epilepsy	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Difficulty thinking or processing information; confusion	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Difficulty with concentrating or maintaining attention	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Poor memory	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Difficulty speaking or talking, slurred speech	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Hyperactivity	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Learning difficulties, dyslexia	<input type="checkbox"/> 0	<input type="checkbox"/> 1	<input type="checkbox"/> 2	<input type="checkbox"/> 3
Other problem, concern, or question in this area?	<input type="checkbox"/> NO	<input type="checkbox"/> YES→		

Additional notes or comments:

Interpretation of iron status based on serum ferritin (in descending order)	
Ferritin	Categorization and management
≥ 800 mcg/L	Practically diagnostic of severe iron overload ⁶⁴³ ; Repeat tests; rule out inflammation or occult pathology. Initiate phlebotomy and consider liver biopsy or MRI.
≥ 300 mcg/L	Probable iron overload; clear predisposition to iron accumulation ⁶⁴⁴ ; Repeat tests; rule out inflammation or occult pathology. In men, initiate phlebotomy and consider liver biopsy or MRI. ⁶⁴⁵
≥ 200 mcg/L	In women: Probable iron overload; clear predisposition to iron accumulation ⁶⁴⁶ ; Repeat tests, rule out inflammation or occult pathology. In men, initiate phlebotomy and consider liver biopsy or MRI. ⁶⁴⁷
≥ 160 mcg/L	In women: Abnormal iron status ⁶⁴⁸ ; Repeat tests, rule out inflammation or occult pathology. Consider phlebotomy and liver biopsy or MRI.
≥ 80-120 mcg/L	High-normal unhealthy iron status ^{650,651} ; No follow-up is mandated; blood donation and abstinence from dietary iron are suggested preventative healthcare measures. A subset of patients with restless leg syndrome (RLS, a condition also causally associated with intestinal bacterial overgrowth dysbiosis) have impaired transport of iron into the brain and therefore require slightly elevated ferritin/iron levels (up to 120) to enhance cerebral iron uptake.
40-70 mcg/L	Optimal iron status for most people ^{652,653}
< 20 mcg/L	Iron deficiency: Search for occult gastrointestinal blood loss with endoscopy or imaging assessments in adults; refer to gastroenterologist. ^{654,655}

⁶⁴³ Milman N, Albeck MJ. Distinction between homozygous and heterozygous subjects with hemochromatosis using iron status markers and receiver operating characteristic (ROC) analysis. *Eur J Clin Biochem* 1995; 33: 95-8. See also Milman N. Iron status markers in hereditary hemochromatosis: distinction between individuals being homozygous and heterozygous for the hemochromatosis allele. *Eur J Haematol* 1991; 47:292-8.

⁶⁴⁴ Olynyk JK, Bacon BR. Hereditary hemochromatosis: detecting and correcting iron overload. *Postgrad Med* 1994;96: 151-65.

⁶⁴⁵ Barton JC, Edwards CQ, Bertoli LF, Sawyer TW, Hudson SL. Iron overload in men with serum ferritin levels of 300 microg/L or more and in women with serum ferritin levels of 200 microg/L or more, regardless of the presence or absence of symptoms. Barton JC, McDonnell SM, Adams PC, Brissot P, Powell LW, Sullivan JL, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. *Ann Intern Med* 1998 Dec 1;129(11):932-9.

⁶⁴⁶ Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. *Circulation* 1992; 86: 803-11.

⁶⁴⁷ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.

⁶⁴⁸ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.

⁶⁴⁹ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.

⁶⁵⁰ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.


⁶⁵¹ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.

⁶⁵² Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.

⁶⁵³ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.

⁶⁵⁴ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.

⁶⁵⁵ Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981 Jun 13;1(8233):1293-4.



Guide to Patient Management Based on Iron Status:

- Deficiency:** Adult patients with iron deficiency must generally be presumed to have occult gastrointestinal blood loss and should therefore be referred for gastrointestinal endoscopy; this is consistent with the standard of care in medicine.
- Optimal:** Ferritin levels between 40-70 mcg/L are generally optimal for most men and women; up to 120 mcg/L is reasonable for subsets of patients with restless leg syndrome, perhaps also those with recalcitrant depression and/or Parkinsonian features to allow sufficient iron entry into the brain for maximal dopamine production.
- Excess:** Levels greater than 200 mcg/L in a woman or 300 mcg/L in a man are suggestive of iron overload and/or tendency toward accumulation and are physiologically unnecessary and medically unjustified, particularly as increased iron stores correlate with increased cancer mortality, increased cardiovascular mortality, and increased all-cause mortality.
- Overload:** Diagnosis and treatment for iron overload can occur simultaneously with diagnostic/therapeutic phlebotomy. Genetic testing and liver biopsy are generally inefficient expenditures of financial and human resources; genetic testing is largely irrelevant in the presence of the hemochromatosis phenotype (otherwise inexplicable iron accumulation) while liver biopsy exposes the patient to unnecessary treatment delays, risk, and expenses. Identification of idiopathic or genotrophic iron overload requires testing of first-degree relatives.



- Thyroid assessment: may show evidence of diabetes and hyperthyroidism or hypothyroidism in patients with iron overload.
- Bone marrow biopsy: unnecessary and archaic in this setting.
- Liver biopsy: traditionally considered the “gold standard” but is clearly unnecessary for the diagnosis, which can be established by phlebotomy, which is the treatment of choice.⁶⁵⁶ **Life-threatening iron overload should never be denied or delayed for lack of liver biopsy.**⁶⁵⁷
- Genetic testing, such as for the HFE mutation: This is not recommended in clinical situations; these tests should be reserved for research purposes, especially in children—of index cases. The only value that is in supporting a diagnosis in a patient with elevated serum ferritin is by phlebotomy; however, a negative result is meaningless if the patient is compatible with iron overload. If the diagnosis is established by phlebotomy.

Establishing the diagnosis: Any *one* of the following three is sufficient:


- Diagnostic liver biopsy shows heavy iron deposits.
- Characteristic laboratory findings (ferritin >200 in women or >300 in men) **and** the ability to resist intractable anemia with serial/weekly phlebotomies.
- Characteristic MRI of liver **and** the ability to tolerate serial/weekly phlebotomies.

Complications:

- Patients diagnosed *and effectively treated* before the onset of complications.
- The most common causes of premature mortality in undiagnosed iron overload are heart failure, liver failure, infections and/or complications of dialysis.

Clinical management:

- Treatment for severe iron overload is iron-removal therapy. Therapeutic phlebotomy—is the treatment of choice. Defective iron metabolism who refuse or cannot withstand phlebotomy (i.e., patients with a mutation in the HFE gene) are much less effective, much more expensive, and much less effective.



Algorithm for the comprehensive management of iron status: The above flow-chart delineates patient management per iron status.

Basic treatments for severe iron overload:

- Iron-removal therapy is mandatory:** Phlebotomy therapy is generally performed weekly or twice-weekly. Deferoxamine chelation is reserved for patients who do not withstand phlebotomy (due to cardiomyopathy, severe anemia, or hypoproteinemia) or may be used concurrently with phlebotomy in some patients. Periodically assess hematologic and iron indexes. Continue with weekly iron removal therapy until patient reaches mild iron-deficiency anemia, then decrease frequency and continue phlebotomy as needed (e.g., 4 times per year).

Laboratory tests and physical examination: Assess general physical condition and hepatic, cardiac, endocrine, and general health status.

Confirm diagnosis: Liver biopsy ("gold standard") or diagnostic phlebotomy; perhaps MRI.


Assess liver status: Liver biopsy or perhaps MRI. Cirrhosis indicates increased risk of hepatocellular carcinoma and reduced life expectancy. Consider liver ultrasound, serum liver enzyme measurement, and serum alpha-fetoprotein to screen for hepatocellular carcinoma every 6 months. Hepatoma surveillance is mandatory in cirrhotic patients.

Implement dietary modifications and nutritional therapies: Avoid iron supplements, multivitamin supplements with iron, iron-fortified foods, liver, beef, pork, alcohol, and excess vitamin C. Ensure adequate protein intake to replace protein lost during phlebotomy. Diet modifications.

25(OH)D: serum 25(OH) vitamin D

Overview and interpretation:

- Vitamin D deficiency is a common cause of musculoskeletal pain.^{170,171} deficiency is a significant risk factor for cancer, autoimmunity, diabetes, chronic pain and physical disability.^{173,174,175}
- Measurement of serum 25(OH) vitamin D (or empiric treatment with vitamin D3 per day for adults) is indicated in patients with chronic musculoskeletal pain, particularly low-back pain.¹⁷⁶ Optimal vitamin D status correlates with levels of 50 – 100 ng/mL (125 – 250 nmol/L)—see our review article for details. Levels greater than 100 ng/mL are unnecessary and increase the risk of



Interpretation of serum 25(OH) vitamin D levels. Modified from *Alternative Therapies in Health and Medicine* 2004 and *Vasculitis: Expanded Clinical Strategies* 2008.

Advantages:	<ul style="list-style-type: none"> Accurate assessment of vitamin D status.
Limitations:	<ul style="list-style-type: none"> Patients with certain granulomatous conditions such as sarcoidosis and patients taking certain drugs such as thiazide diuretics (they develop hypercalcemia due to "vitamin D hypersensitivity" or patients require frequent monitoring of serum calcium while taking these supplements).
Comments:	<ul style="list-style-type: none"> Routine measurement and/or empiric treatment with vitamin D is a routine component of patient care.¹⁷⁸ Periodic assessment of 25(OH)D and serum calcium are required for safety of treatment, respectively. I'm increasingly convinced of the merit of measuring 1,25-dihydroxyvitamin D for the initial assessment of patients with inflammatory/autoimmune disease.

Vitamin D, 1,25 + 25-Hydroxy		Low	Normal	High	Reference Range	Units
Test					10.0-75.0	pg/mL
Calcitriol(1,25 Di-Oh Vit D)			53.1	115.8	30.0-100.0	ng/mL
Vitamin D, 25-Hydroxy		Low	Normal	High	Reference Range	Units
Cmp14+Egfr			90		65-99	mg/dL
Test					6-20	mg/dL
Glucose, Serum			20		0.76-1.27	mg/dL
Bun			0.93		>59	mL/min/1.73
Creatinine, Serum			104		>59	mL/min/1.73
Egfr # Nonafric Am			120		8-19	1
Egfr # Afric Am				22	134-144	mmol/L
Bun/Creatinine Ratio			142		3.5-5.2	mmol/L
Sodium, Serum			4.8		97-108	mmol/L
Potassium, Serum			99		18-29	mmol/L
Chloride, Serum			26		8.7-10.2	mg/dL
Carbon Dioxide, Total			9.7			
Calcium, Serum						

Cbc/Diff Ambiguous Default

Test	Low	Normal	High	Reference Range	Units
Wbc		5.8		3.4-10.8	x10E3/uL
Rbc		5.26		4.14-5.80	x10E6/uL

Ldh

Test	Low	Normal	High	Reference Range	Units
Ldh		123		121-224	IU/L

Homocyst(E)ine, Plasma

Test	Low	Normal	High	Reference Range	Units
Homocyst(E)ine, Plasma		10.7		0.0-15.0	umol/L

Laboratory results for a 39yoM with psoriasis and psoriatic arthritis: Abnormally increased conversion of 25-OH-cholecalciferol to 1,25-diOH-cholecalciferol is due expression of 25-hydroxyvitamin D3-1alpha-hydroxylase (1-OHase) in inflammatory tissue/cells. Note that serum calcium is normal, so no immediate threat is present (i.e., hypercalcemia) but of course the clinician has the responsibility to monitor periodically, inform the patient of symptoms of hypercalcemia such as headache and abdominal pain, and search for any predictive risk factors such as renal insufficiency or occult leukemia/lymphoma that could precipitate hypercalcemia. Assessment for hyperparathyroidism (eg, iPTH) is reasonable but not completely necessary; likewise, cancer screening is not absolutely indicated, as it would be in the case of idiopathic hypercalcemia. Also noted is the elevated homocysteine, common in patients with psoriasis; increased cell turnover—dermal hyperproliferation—likely contributes to draining/catabolizing nutrients such as folate. Since this patient's 25-OH-D is plenty sufficient, I had the patient temporarily reduce/discontinue vitamin D supplementation to reduce risk of hypercalcemia given that he is clearly vitamin D sufficient.

CME

CONTINUING MEDICAL EDUCATION

THE CLINICAL IMPORTANCE OF VITAMIN D (CHOLECALCIFEROL): A PARADIGM SHIFT WITH IMPLICATIONS FOR ALL HEALTHCARE PROVIDERS

Alex Vasquez, DC, ND, Gilbert Manso, MD, John Cannell, MD

Alex Vasquez, DC, ND is a licensed naturopathic physician in Washington and Oregon, and licensed chiropractic doctor in Texas, where he maintains a private practice and is a member of the Research Team at Biotics Research Corporation. He is a former Adjunct Professor of Orthopedics and Rheumatology for the Naturopathic Medicine Program at Bastyr University. Gilbert Manso, MD, is a medical doctor practicing integrative medicine in Houston, Texas. In prac-

tice for more than 35 years, he is Board Certified in Family Practice and is Associate Professor of Family Medicine at University of Texas Medical School in Houston. John Cannell, MD, is a medical physician practicing in Atascadero, California, and is president of the Vitamin D Council (Cholecalciferol-Council.com), a non-profit, tax-exempt organization working to promote awareness of the manifold adverse effects of vitamin D deficiency.

InnoVision Communications is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The learner should study the article and its figures or tables, if any, then complete the self-evaluation at the end of the activity. The activity and self-evaluation are expected to take a maximum of 2 hours.

OBJECTIVES

Upon completion of this article, participants should be able to do the following:

1. Appreciate and identify the manifold clinical presentations and consequences of vitamin D deficiency
2. Identify patient groups that are predisposed to vitamin D hypersensitivity
3. Know how to implement vitamin D supplementation in proper doses and with appropriate laboratory monitoring

Reprint requests: InnoVision Communications, 169 Saxony Rd, Suite 103, Encinitas, CA 92024; phone, (760) 633-3910 or (866) 828-2962; fax, (760) 633-3918; e-mail, alternative.therapies@innovision.com. Or visit our online CME Web site by going to <http://www.alternative-therapies.com> and selecting the Continuing Education option.

While we are all familiar with the important role of vitamin D in calcium absorption and bone metabolism, many doctors and patients are not aware of the recent research on vitamin D and the widening range of therapeutic applications available for cholecalciferol, which can be classified as both a vitamin and a pro-hormone. Additionally, we also now realize that the Food and Nutrition Board's previously defined Upper Limit (UL) for safe intake at 2,000 IU/day was set far too low and that the physiologic requirement for vitamin D in adults may be as high as 5,000 IU/day, which is less than half of the >10,000 IU that can be produced endogenously with full-body sun exposure.^{1,2} With the discovery of vitamin D receptors in tissues other than the gut and bone—especially the brain, breast, prostate, and lymphocytes—and the recent research suggesting that higher vitamin D levels provide protection from diabetes mellitus, osteoporosis, osteoarthritis, hypertension, cardiovascular disease, metabolic syndrome, depression, several autoimmune diseases, and cancers of the breast, prostate, and colon, we can now utilize vitamin D for a wider range of preventive and therapeutic applications to maintain and improve our patients' health.³ Based on the research reviewed in this article, the current authors believe that assessment of vitamin D status and treatment of vita-

Vasquez A et al. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all healthcare providers. *Altern Ther Health Med* 2004 Sep-Oct: This article indexed on Medline at ncbi.nlm.nih.gov/pubmed/15478784 and is archived by the author online ICHNFM.ORG/faculty/vasquez/profile.html and <https://ichnfm.academia.edu/AlexVasquez>

Copyrights: © 2004-present by Dr Alex Vasquez. All rights reserved by the author and enforced to the full extent of legal and financial consequences internationally. No part of this book may be reproduced, stored in a retrieval system, used for the creation of derivative works, or transmitted by any means (electronic, mechanical, photocopying, recording, or otherwise) without written permission from the author.



Trademarks: ® 2013-present by Dr Alex Vasquez and International College of Human Nutrition and Functional Medicine. The functional immunology/inflammation protocol discussed in this series of videos/notes/books/audios is recalled by the F.I.N.D.S.E.X. acronym trademarked™ in association with Dr Vasquez's books and videos including but not limited to Functional Immunology and Nutritional Immunomodulation (2012), F.I.N.D. S.E.X. The Easily Remembered Acronym for the Functional Inflammation Protocol (2013), Integrative Rheumatology and Inflammation Mastery, 3rd Edition (2014). Portland, Oregon; Integrative and Biological Medicine Research and Consulting, LLC. All rights reserved and enforced. For additional information and resources, see InflammationMastery.com and/or FunctionalInflammation.com. Additional trademarks referenced/cited in this work include International College of Human Nutrition and Functional Medicine®, International Conference on Human Nutrition and Functional Medicine®, and *International Journal of Human Nutrition and Functional Medicine*®.



Intellectual property: This book contains the creative work and intellectual property of Dr Alex Vasquez, owned and protected internationally by Dr Alex Vasquez, Integrative and Biological Medicine Research and Consulting ("IBMRC") LLC, and International College of Human Nutrition and Functional Medicine ("ICHNFM" and "ICHNFM.ORG"), based in North America and Europe. Except for quotes and excerpts from other sources, all of the information and images are protected by copyright ©; phrases and terms such as the FINDSEX ® acronym are additionally protected by registered trademark. The book is the means of licensed transmittal of this intellectual property; ownership of the book as an instance of licensed private transmittal and access does not equate to ownership of the property. The book also provides individual, private access to proprietary video archives. This work is supported and made possible by revenue from book sales, and readers/purchasers are asked and expected to respect the author's ownership of the work—specifically to not inappropriately copy or distribute—so that this work can continue. Violations of intellectual property rights, copyrights, and trademarks will be pursued to the highest extent possible internationally. For use permissions and to report violations, please contact admin@ichnfm.org.


Notices: The intended audiences for this book are health science students and doctorate-level licensed medical clinicians. This book has been written with every intention to make it as accurate as possible, and each section has undergone peer-review by an interdisciplinary group of clinicians. In view of the possibility of human error and as well as ongoing discoveries in the biomedical sciences, neither the author nor any party associated in any way with this text warrants that this text is perfect, accurate, or complete in every way, and all disclaim responsibility for harm or loss associated with the application of the material herein. Information and treatments applicable to a specific *condition* may not be appropriate for or applicable to a specific patient; this is especially true for patients with multiple comorbidities and those taking pharmaceutical medications, which are generally associated with multiple adverse effects and drug/nutrient/herb interactions. Given that this book is available on an open market, lay persons who read this material should discuss the information with a licensed medical provider before implementing any treatments and interventions described herein.

Reviews of previous and recent works:


- "Thank you most kindly for your incredible dedication and kindness in sharing your knowledge with us. I am due to start med school next semester and thanks to you and all those who have taught you, I'll be way ahead of the curve." *Premedical/Medical student 2015*
- "Dr Vasquez, I have followed your work extensively and admire your intellect and passion. Thank you for your passion for teaching with integrity!" *Chiropractic doctor 2015*
- "I just wanted to tell you how much I appreciate the information I have received from you. I am still digesting most of it. I feel I have learned quite a bit already yet also feel I have barely scratched the surface." *Doctor and Graduate student under Dr Vasquez, 2013*
- "Dr. Vasquez, Thank you for all you do. **Your conference was simply amazing.** No one wanted to leave the room. I met medical professionals and very interesting lay people who were stimulated and invigorated to change their lives and the lives of others. **I am in awe at your intellectual integrity and veracity.** Best of luck to you in all of your future endeavors." *Medical physician and ICHNFM 2013 Conference Attendee*
- **2014 review of Functional Inflammolgy, Volume 1: "A truly comprehensive text on the vast subject of inflammation. I consider this book to be an essential addition to any health care practitioner who wishes to operate within the realm of Function Medicine. Please be aware that this book is dense in its content, and its 700 plus pages are full of deeply insightful information. I think Dr. Vasquez is one of the most prolific functional medicine contributors and books such as this should cement his reputation as such."**
- "I attended the last ICHNFM conference in Portland (and am still basking in the amazing information received)." *Email from Clinical Oncology Dietitian, in late February 2014*
- "Thanks for a fantastic conference!" *ICHNFM 2013 Conference Attendee*
- "Your discourse today reflected not only your passion and commitment to the wellness of our planet but most importantly the clarity and sincerity of your spirit/ heart/ mind. Always good to be with you and look forward to seeing you soon. Hope we can spend more time then." *Medical physician attendee 2014*
- "I was so refreshed by the **unfiltered excellence.**" What humanness. Breaths of fresh air." *ICHNFM 2013 Attendee*
- "Keep in mind Alex, that humanity is a better place because of you. I know you can't undo it all, but think about how many people would be worse off if it wasn't for your wonderful knowledge being shared with all us docs. Things that I have learned from you have changed peoples' lives for the better." *Naturopathic physician, 2014*
- "Just got back to Guam. Great experience at the International Conference on Human Nutrition and Functional Medicine. Exciting concepts on functional medicine. Thanks Dr. Alex Vasquez and team!" *ICHNFM 2013 Conference Attendee*
- "Already waiting in line to buy next year's ticket! **Dr. Vasquez you crushed it!** The future is looking fun already ☺" *ICHNFM 2013 Conference Attendee*
- "Had an incredible time at the 2013 International Conference on Human Nutrition and Functional Medicine. Got to meet some amazing people and hear from some of the top researchers/health professionals about human nutrition and functional medicine approaches. It was definitely worth every penny and can't wait to go back next year!" *ICHNFM 2013 Conference Attendee*
- "I miss you! Your confidence in a program you believed in. I miss your live classes where we would get off topic on a clinical pearl. I miss your way of teaching in a laid back atmosphere that made me feel comfortable, not intimidated. I just needed to let you know, this program is not the same, I am almost done, otherwise, I would have bailed out! I am grateful for the last 18 months I did have with you at the helm. ... You ignited in me my passion for learning again. You sparked the minds of all of us with your enthusiasm. Don't ever let anyone take that away. It has given birth to your new endeavor, and we will follow where you lead. Enjoy your new surroundings and celebrate your new beginnings. I know I look forward to what is ahead." *Doctor and Graduate student under Dr Vasquez, 2013*
- "Wonderful conference! Thanks so much." *ICHNFM 2013 Conference Attendee*
- "Really wonderful conference! Lots of material ready to implement Monday morning! **Congrats to Alex Vasquez on a herculean job very well done!**" *ICHNFM 2013 Conference Attendee*
- "Thanks for a great conference. I really enjoyed all of the speakers, but your lectures were by far the most useful for implementing ideas into my clinical practice. And the most entertaining." *ICHNFM 2013 Conference Attendee*
- "Thank you for your life-changing work." *Physician, 2011*
- "I want Dr. Vasquez to know that I have just received his book, *Chiropractic and Naturopathic Mastery of Common Clinical Disorders*. **It is a treasure. The best book in my library.** Thank you for the contribution that you are giving to the world of health care." *Clinician, 2010*
- "I appreciate the resources you offer the profession. I use your books and articles regularly." *Doctor, 2011*
- "Dr. Vasquez, I greatly appreciate your efforts. I am a student at ___, 8th trimester, and would like to express my gratitude for your research and works. After coming across your texts in the library, **I quickly found your insight and explanations of the current health care crisis, and in depth coverage and algorithms for inflammatory**

diseases as a profound inspiration and call to action. I appreciate your attention to detail, and have been taken back several times by the potency and meaning of your sentences. Thank you for your hard work, I will enjoy these books and will surely share with those that have the same drive for true and competent patient care." *Health Sciences Student, 2008*

- "I never told you this, but whenever I need to research a particular disease, **besides going on Pubmed and checking some classic Pathophysiology and Clinical Nutrition books, I use your books and I find them extremely well organized, concise, and up-to-date and with the functional/integrative medicine thinking I enjoy and believe it is the future of Health Care.**" *Nutrition Research Consultant and University Faculty in Europe, 2009*
- "Thanks so much. You are a great asset to our profession." *Doctor, 2010*
- "As a 7th trimester student quickly approaching 8th trimester and student clinic, I know I will be utilizing your books often. **Your "Chiropractic and Naturopathic Mastery of Common Clinical Disorders" book is referenced very frequently by many clinicians and faculty members at [our university]. Your work is highly regarded,** and I look forward to clinically utilizing the information I will obtain from your writings." *Health Sciences Student, 2011*
- "I am a chiropractic student at ___ Chiropractic College. I just wanted to drop a quick line thanking you for your thorough and accessible textbook Integrative Orthopedics. We are using it in our Differential Diagnosis class, and **it is the best book I've come across in Chiropractic College bar none. The writing is concise, informative and refreshingly eloquent. The material is super practical. I hope you continue putting out great resources.**" *Health Sciences Student, 2011*
- "I appreciate the resources you offer the profession. **I use your books and articles regularly.**" *Doctor, 2011*
- "**Your Integrated Orthopedics book is magnificent.** I wish all textbooks were structured and as thoughtful as that one." *Health Sciences Student, 2008*
- "By reading the introduction I realize that calling it an orthopedics book; does not do it justice. **It is far more than that. It looks to me that you have created, or are creating, the bible of Integrative Orthopedics and physical medicine.**" *Physician, 2007*
- "First of all let me say how honored I am that you have allowed me to review this work. You have done an amazing job! In my opinion **every healthcare provider SHOULD have this on their bookshelf.**" *Physician, 2007*
- "Your work on Chapter 12: Hip and Thigh is very good. The chapter is inclusive of the typical pathologies seen in private practice and I particularly liked the separation of juvenile from adult pathologies. Your choice of tests to assess hip and thigh pathology on page 320 is very nice and inclusive. I appreciate your use of algorithms and find them very useful in teaching and in practice. In general, **I thought this chapter represents a quality, state of the art presentation!**" *Clinician and Professor in Clinical Sciences, 2007*
- "I saw your books in a colleague's office and was really impressed. Really appreciate the thoroughness you've put into them." *Doctor, 2010*
- "**It is with great interest and fascination that I have been reading your material both in your two books (Integrative Orthopedics and Integrative Rheumatology) and online. I consider myself very fortunate to have come across your work,** as many of the basic elements of health which you discuss I never learnt or even heard about while in chiropractic college." *Doctor, 2010*
- "I appreciate the resources you offer the profession. I use your books and articles regularly." *Doctor, 2011*
- "**I'm so pleased with your books and was inspired to let you know they have already been incredibly useful! Good index; well organized algorithms. Sometimes I buy educational material and it just sort of sits there... Your books now live on my main desk. Thanks.**" *Physician and Journal Editor, 2009*
- "I just wanted to let you know how much I am enjoying reading **your book Integrative Rheumatology. It is having an extremely positive impact in the way I view health and am having a tough time putting it down. It is very inspirational.** I have long felt that it is very important to set a good example for your patients and now try my best to be one for my future patients. I like how you stress this in your book. In order to be the best example for my patients I am going to need to address some problems with my own health. I look healthy from the outside but I have been suffering from fatigue for about 4 years. It has a very negative impact on my health. People say that doing the same thing and expecting different results is the definition of insanity so I think it is time that I attempt to make some changes. ... **Thanks again for writing such a great book. I feel it is a must have for anyone in a musculoskeletal practice.**" *Health Sciences Student, 2010*
- "My name is [recent graduate], and I've been a fan of your books since I was in chiropractic college at [university] campus. Dr. [Author, Presenter] made your book, Integrative Rheumatology, required reading for his 9th quarter nutrition class. I never looked back, and have since purchased Chiropractic & Naturopathic Mastery of Common Clinical Disorders as well as Chiropractic Management of Chronic Hypertension." *Doctor, 2010*
- "I saw your books in a colleague's office and was really impressed. Really appreciate the thoroughness you've put into them." *Doctor, 2010*



Excerpt copyright © by Dr Alex Vasquez and International College of Human Nutrition and Functional Medicine www.ICHNFM.ORG. From *Inflammation Mastery 4th Edition*, also printed as a two-volume set as *Textbook of Clinical Nutrition and Functional Medicine*. All rights reserved and enforced internationally. See ICHNFM.ORG for details, videos, discounts.



Blood cells in FM patients show mitochondrial destruction (mitophagy), smaller size and lower number of mitochondria: Structure of blood mononuclear cells (BMCs, cells of the immune system) from FM patients. The healthy/control BMCs show mitochondria with a normal structure. Autophagosomes (indicated by arrows), where mitochondria are destroyed (the process of mitophagy [mito-mitochondria, phagy-consumption]), are noted in the BMCs of patients with FM. (Bar = 1 micrometer). This open access image is respectfully attributed to the brilliant research published by these researchers: Cordero MD, De la Haza M, Moreno Fernández AM, Carmona López JM, Garrido Maraver J, Cotán D, Gómez Izquierdo L, Bonal P, Campa F, Bullón P, Navas P, Sánchez Alcaraz JA. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients. *Arthritis Res Ther*. 2010;12(1):R17. arthritis-research.com/content/12/1/R17

Mitophagy: The body's inherent mechanism for the destruction of dysfunctional mitochondria

Concept: Autophagic destruction of mitochondria is termed "mitophagy" and is the body's inherent mechanism for eliminating superfluous or dysfunctional mitochondria; this generally has a protective and life-sustaining effect. However, in the case of fibromyalgia wherein the mitochondrial dysfunction is persistent, prolonged mitophagy contributes to failure of adequate energy production and thereby contributes to clinical manifestations of fatigue, dyscognition, and impaired exercise/activity performance. Further, the consistent documentation of significant mitophagy in patients with fibromyalgia proves the biological/organic/real/pathophysiological character of the illness and refutes the pharmacocentric paradigm which holds that the condition is of psychogenic or neurologic origin and thus to be treated with so-called "antidepressants" and/or analgesic drugs, respectively.


- The removal of damaged mitochondria that could contribute to cellular dysfunction or death is achieved through process of mitochondrial autophagy, i.e. mitophagy. • Novak I. *Antioxid Redox Signal*. 2011
- Mitochondrial number and health are regulated by mitophagy, a process by which excessive or damaged mitochondria are subjected to autophagic degradation. • Rambold. *Cell Cycle*. 2011
- "Autophagy can be beneficial for the cells by eliminating dysfunctional mitochondria, but massive autophagy can promote cell injury and may contribute to the pathophysiology of FM." • Cordero. *Arthritis Res Ther*. 2010

• **Pain in fibromyalgia originates peripherally and is amplified centrally:** The pain of fibromyalgia originates from the muscles²⁵⁰ secondary to stimulation by oxidative and inflammatory mediators and is excessively amplified in the brain and spinal cord; another possible peripheral contribution to pain inputs is degeneration of nerve fibers in the skin.²⁵³ To risk redundancy for clarity: FM pain originates *peripherally* in the muscles

Chapter 5.1—Functional Inflammation Protocol for Metabolic Inflammation: Migraine & Fibromyalgia

(and likely in the skin as well, at least in some patients) and is amplified centrally in the spinal cord and grows both in size and intensity/hypersensitivity to include the skin, so that various skin inputs are perceived stimuli as pain) and hyperalgesia (extended duration and increased intensity of pain).

• **Enhanced central pain processing of fibromyalgia:** patients is maintained by muscle afferent input (Pain, hyperalgesia in FM patients, emphasizing the important role of peripheral impulse input in maintaining central sensitization in this chronic pain syndrome; similar to other persistent pain conditions such as irritable bowel syndrome and complex regional pain syndrome."



More than 400 years of the history and development of neuroanatomy and neurophysiology represented in four images: These four images in sequence represent the history and development of the fields of neuroanatomy and neurophysiology. 1. The drawing by Descartes in the 1600s. 2. The tracing of nerves throughout the body. 3. What might be called the starting with the drawing by Descartes in the 1600s. 4. The tracing of nerves throughout the body. Findings suggest that some patients with chronic pain labeled as fibromyalgia have unrecognized SPN, a distinct disease that can be tested for objectively and sometimes treated definitively. • Oaklander et al. Objective evidence that small fiber polyneuropathy underlies some chronic central pain. *Pain*. 2013 Nov;154(11):2358-64. • Staud et al. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input. *Pain*. 2008 Sep;143(3):526-34.


Excerpt copyright © by Dr Alex Vasquez and International College of Human Nutrition and Functional Medicine ICHNFM.ORG. From *Inflammation Mastery 4th Edition*, also printed as a two-volume set as *Textbook of Clinical Nutrition and Functional Medicine*. All rights reserved and enforced internationally. See ICHNFM.ORG for details, videos, discounts.

Food-Induced Activation of Toll-like Receptors, Endoplasmic Reticulum Stress, and the Unfolded Protein Response: An Integrated Model for Understanding Metabolic Inflammation


Metabolic Inflammation: Diet-Induced Metabolic Impairment and Inflammation

In this section, I will describe and give structure to a model for understanding what I have previously described—albeit intuitively—as metabolic inflammation.

Introduction: In my model presented starting in 2012,⁶⁵ I began differentiating/describing inflammatory conditions as existing along and within an *overlapping continuum* of 1) metabolic inflammation, 2) allergic inflammation, and 3) autoimmune inflammation. The most basic definition/description of metabolic inflammation is simply that it is a pathophysiological state of nonacute metabolic disruption/dysfunction combined with a state of chronic/sustained mild/nonacute inflammation. What I have also stated is that "chronic inflammation" as most of us were taught in our Pathology coursework does not—for the most part—exist; except for a few rare diseases, the body does not perpetuate clinically significant states of inflammation. So-called *chronic inflammation* only occurs via a *sustained inflammatory response*. Another newer—and perhaps more direct way—of shattering the outdated paradigm of "chronic disease" is to state that such diseases do not exist—only responses and accumulated damage exist. Clinicians should experiment with the possibilities and implications of exchanging their conception of "chronic diseases" in favor of "sustained responses"; I think they will find the experience to be more illuminating/empowering/engaging than resignation to the chronic disease model and its subsequent indefinite noncurative (poly)pharmacotherapy. The illustration below introduces and summarizes several key concepts.



Metabolic, microbial, and xenobiotic insults—often via TLR4—induce endoplasmic reticulum stress (ERS) and the subsequent unfolded protein response (UPR): Consequences include vicious cycles of inflammation, oxidative stress, mitochondrial dysfunction, insulin resistance and hyperphagia—all consistent with sustained sterile, nonacute inflammation and metabolic dysfunction/impairment termed here as *metabolic inflammation*.




Schematic overview of mitochondrial dysfunction's major causes and consequences: Notice the presence of vicious cycles whereby cause becomes consequence, and then consequence becomes cause. Several dietary, nutritional, botanical, pharmaceutical/microbiologic, and sociopolitical interventions are obvious from the diagram.

Mitochondria—Re-introduction and New Perspectives:

- **Production of cellular energy in the form of ATP:** Mitochondria are organelles ("small organs") within each cell that produce the majority of cellular energy for biochemical reactions and cellular processes. The primary fuel used by cells of the body is ATP—adenosine triphosphate. Everyone who has studied mitochondria—ranging from high-school and undergraduate students of Biology all the way to doctorate-level medical/healthcare professionals—is familiar with the fact that mitochondria make ATP; in fact, for most people, whether they are general public or doctors, this is all they know about mitochondria. New research, however, has shown us that mitochondria have many roles in addition to their ability to produce cellular energy. Most importantly, mitochondria are now known to play important roles in perpetuating chronic inflammation, responding to microbial infections, triggering cell death, and controlling various metabolic processes.^{1,2}
- **Perpetuation of chronic inflammation:** Most relevant to the focus of this work on clinical conditions related to inflammation is the fact that mitochondria have the ability to trigger inflammatory responses via activation of the nuclear transcription factor kappa-B (NFkB). Transcription factors are intracellular molecules that bind to the genetic material (DNA) in the nucleus of the cell to influence the activation or transcription of specific genes; inflammatory responses—necessary for short-term responses to injury or infection, but harmful when protracted and nonspecific. In this way, certain types of mitochondrial stimulation/activation/dysfunction can

¹ Flomench SB, Nemeroff B. Mitochondrial dysfunction and metabolic pathways of disease. *Exp Med Pathol*. 2007 Aug;30(1):84-92.
² Green DR, Galluzzi L, Kroemer G. Mitochondria and the ubiquitin-proteasome pathway: how and why they interact to control cell fate. *Nat Rev Mol Cell Biol*. 2008 Sep;9(9):681-91.

ers more glial activation,
and a vicious cycle



able to normal activity
ts and stressors
emotional stress.
o neurons, leading to

ntly show evidence of mitochondrial impairment:
ng 1) defects in CoQ10 synthesis, 2) defects in
(ETC). The majority of these problems can be
dysfunction promotes inflammation in microglia:
el mitochondria promote microglial activation.
of Complex #4 in the electron

amply, and excessive inflammation caused by increased neuroactivity—that is phenotypically ready to perceive, this context, including the microglia and astrocytes as components of the brain and spinal cord) neuroinflammation would be expected to participate in seizure disorders and vaccine-induced encephalomyelitis.

4. **Image lower right—The nervous system (represented by artistic brain image) is now appreciated as dynamic and interactive receiver and processor of sensory information:** In modern times, pain processing is appreciated as a dynamic, complex, and interactive process at every level, from peripheral reception of stimuli (e.g., in the skin or muscles), to the spinal cord, to the brainstem, to the subcortical structures especially the thalamus, to the cortex. Generally appreciated is that much “spill-over,” misinterpretation, inhibition and amplification” can occur in the spinal cord, brainstem, and cortex of the brain, so that the perception of pain—in the muscles for example in the case of FM—is amplified (intensity and duration). The brain is constantly adapting to input; for various patterns to produce memory. When the brain is constantly adapting to input, it facilitates the perception of pain, leading to enhanced pain perception, e.g.

Excerpt copyright © by Dr Alex Vasquez and
International College of Human Nutrition
and Functional Medicine ICHNFM.ORG

Diagnosis


- Clinical criteria—description and contrast of the 1990 criteria and the 2010 criteria: Per guidelines published in 1990 by the American College of Rheumatology (ACR), a diagnosis of fibromyalgia can be made in a patient with inexplicable, widespread myofascial pain of at least 3 months' duration; *inexplicable* denotes normalcy of routine laboratory and physical examination findings and failure to find an alternate explanation or diagnosis, while *widespread* denotes bilateral pain above and below the waist not attributable to trauma or rheumatic disease and with pain at 11 of 18 classic tender point locations (see illustration below).

Illustration of the 9 paired locations of FM tender points:


Illustration of the 9 paired locations of T11 tender points:
Pain, on digital palpation, must be present in at least 11 of the following 18 tender point sites:

1. Occiput: at the suboccipital muscle insertions.
 2. Low cervical: at the anterior aspects of the intertransverse spaces at C5-C7.
 3. Trapezius: at the midpoint of the upper border.
 4. Supraspinatus: at origins, above the scapula spine near the medial border.
 5. Second rib: upper lateral to the second costochondral junction.
 6. Lateral epicondyle: 2 cm distal to the epicondyles.
 7. Gluteal: in upper outer quadrants of buttocks in anterior fold of muscle.
 8. Greater trochanter: posterior to the trochanteric prominence.
 9. Knee: at the medial fat pad proximal to the joint line.
- Per 1990 ACR guidelines, the diagnosis of FM is supported when at least 11 out of 18 of these locations are painful. Digital palpation should be performed with an approximate force of 4 k (9 lbs). A tender point has to be painful at palpation, not just "tender."

Per 1990 ACR guidelines, the diagnosis of RA requires the presence of at least 11 out of 18 of these locations are painful. Digital palpation should be performed with an approximate force of 4 kg (9 lbs). A tender point has to be painful at palpation, not just "tender."²⁵⁹



FM tender points are assessed bilaterally at 9 paired sites: (sub)occiput (below the head at the neckline), cervical spine (lower neck), trapezius and supraspinatus (two of the shoulder muscles), second rib (near costosternal [rib-breastbone] junction), lateral epicondyle, gluteal region, greater trochanter, and fat pad of the knees. Tender points are provoked by the clinician's application of approximately 9 pounds of fingertip pressure, which is sufficient to cause blanching of the clinician's nail bed. The tender fibromyalgia are distinguished from myofascial trigger points (MFTP, described by Travell²⁶⁰) and counterstrain tender points (described in the osteopathic literature by Jones²⁶¹). Pain must have been



Gastrointestinal dysbiosis: Assessments

- **History:** Clinicians should suspect gastrointestinal constipation/diarrhea, irritable bowel syndrome, chemical sensitivity, severe allergies, and autoimmune arthritis, and ankylosing spondylitis. Frequent use of antibiotics, by yeast and/or overgrowth of aerobic bacteria. Indications for stool testing; however, clinicians will have no gastrointestinal symptoms *not unnecessary* simply because the patient has no symptoms.
- **Breath testing:** Bacterial overgrowth of the small intestine. Post-carbohydrate hydrogen/methane breath tests can be sufficiently diagnostic.
- **Lactulose-mannitol assay:** The intestinal permeability test. Two tasks: 1) **efficient absorption** of nutrients and microbial antigens, and indigestible carbohydrates. Impairments in nutrient absorption and permeability commonly results in micro- or macro-nutrient deficiencies of microbes, antigens, waste products, and

is dependent upon ROS production. Thus, we see a tripartite relationship between oxidative stress and its hypertensive effects are ROS-dependent and activation leads to increased secretion of IL-17 and TNF α , both of which themselves lead to hypertension itself leads to immune activation. These authors articulated part of the vicious cycle as follows, "Hypertension also increased T lymphocyte production of tumor necrosis factor (TNF) alpha, and treatment with the TNFalpha antagonist etanercept prevented the hypertension and increase in vascular superoxide caused by angiotensin II. These studies identify a previously undefined role for T cells in the genesis of hypertension and support a role of inflammation in the basis of this prevalent disease. T cells might represent a novel therapeutic target for the treatment of high blood pressure."

Immunophenotype imbalance promotes hypertension

Mechanisms include inflammation-driven 1) insulin resistance, 2) endothelial dysfunction, 3) phagocytic production of NADPH oxidase-derived superoxide, 4) augmented actions of angiotensin-II, and 5) excessive actions of Nox2-mediated ROS.

Hypertensive immune imbalance via deficient Treg and excess Th17, IL-17, TNF α

Treg and excess Th17, IL-17
Material/physical (not simply biochemical) predisposition toward inflammation, allergy, and autoimmunity; overproduction of pro-inflammatory and tissue-damaging cytokines which lead to synergistic production of ROS as well as alteration of native molecules and the activation of DAMP receptors (rDAMP), thereby promoting a vicious cycle of tissue damage, metabolic dysfunction, and "inflammation dysfunction."

Immunophenotype imbalance promotes hypertension

Mechanisms include inflammation-driven 1) insulin resistance, 2) endothelial dysfunction, 3) phagocytic production of NADPH oxidase (Nox), augments mROS pro-hypertensive cell signaling. Prohypertensive actions of angiotensin-2 are largely dependent on Nox2-mediated ROS production, which augments prohypertensive cytokine (TNF α) production. Hypertensive HTN patients show elevations in Th17 cells and the proinflammatory cytokines IL-6, IL-17, and TNF α .

Vicious cycles: mtROS is produced by immune activation and also leads to immune activation; immunocyte involvement is significant for the induction of the hypertensive response promoted by angiotensin-2 and mineralocorticoids

- mineralocorticoids
- 1) mtROS-induced mtROS production
 - 2) Immune-driven immune-mediated mitochondrial dysfunction and immune-mediated which promotes
 - 3) mtROS-induced immune imbalance which promotes dysmetabolism, dysinsulinism, hypertension, autoimmunity, etc.
 - 4) Hypertension is itself pro-inflammatory, and the resulting inflammation and ROS sustain the HTN.
- HTN
- Mitochondria
mTOR, and

Mitochondrial dysfunction promotes HTN
Mitochondrial dysfunction promotes HTN via endothelial dysfunction, altered NO bioavailability, and increased oxidative stress by mtROS, and

Mitochondrial dysfunction promotes HTN via dysinsulinism, endothelial dysfunction, altered intracellular signaling mediated by mtROS, and via enhanced elaboration of prohypertensive cytokines, especially IL-17 and TNF α . Mitochondrial dysfunction promotes prohypertensive "priming" of the immune system toward an exaggerated hypertensive response to glucocorticoids and angiotensin-2. Excessive mtROS from the ETC in the form of superoxide leads directly to neutralization of vasodilating nitric oxide and formation of peroxynitrite.

Mitochondrial dysfunction
hyperpolarization, activation of mitochondrial R

Mitochondrial dysfunction
Mitochondrial hyperpolarization, activation of mTOR, and increased mitochondrial ROS production function independently and synergistically to inhibit Treg maturation, to promote Th17 maturation, and to promote molecular damage which provokes additional unnecessary and inflammation. Superoxide responsiveness and inflammation. Superoxide radical combines with and therefore neutralizes what would otherwise be vasodilating nitric oxide resulting in the production of the aggressive free radical peroxynitrite.

The mitoimmunology and mitoinflammation model: Immune phenotype imbalance and mitochondrial dysfunction independently (at least initially) but eventually become interconnected and pathosynergistic. Prolinflammatory cytokines, especially IL-17 and TNF α , promote prohypertensive "priming" of the immune system toward an exaggerated hypertensive response to glucocorticoids and angiotensin-2. Excessive mROS from the ETC in the form of superoxide leads directly to neutralization of vasodilating nitric oxide and formation of peroxynitrite radical.

• Therapeutic nutritional immunomodulation and inflammatory responses are necessary for we can surmise that the "immune system" and inflammatory responses are necessary for the hypertensive clinical phenotype. Prohypertensive hormones such as glucocorticoids and angiotensin II can effect elevated blood pressure through various means, some of which are completely dependent on the effect of mitochondrial oxidative stress and the resultant pro-inflammatory immune response; I have termed this interdependency "mitoimmunology" and "mitoinflammation".

Correction of **mitochondrial dysfunction** and **immunophenotype imbalance** are both now means by which clinicians can modulate dysfunctional pro-hypertensive pathophysiology. Furthermore, we must now appreciate the intimate connection between mitochondrial dysfunction, the role played by intramitochondrial ROS as cell signaling molecules that promote hypertension, and autoimmunity) and the immune system, which can now be seen as the mitochondria's direction. Stated more plainly: Mitochondrial signals (e.g., mtROS) direct the immune system's response of the immune system (which will "over-react" if already in inflammatory imbalance) to promote harmful inflammation, which I categorize as (1) nonpharmadependent means by which clinicians can address hypertension via correction of physiologic function rather than dependence on pharmacotherapy—using a system that is already dysfunctional.

Clinicians have generally considered oxidative stress to be "bad" and antioxidant pharmacologic function rather than dependence on pharmacologic function. Of physiologic function rather than dependence on pharmacologic function, a system that is already dysfunctional.

While this is generally true in a quantitative sense, we as intellectually competent clinicians than such broad categories of "good and bad" given that the information is now efforts of innumerable named/unnamed researchers, their students, and assistants understanding, we need to discern the names and characteristics, roles and compartmentalization of ROS to better appreciate their participation in health and we will be better able to help our patients and strengthen the science of our health.

Mitochondrial/Metabolic Impairment CoQ10 is the most important treatment for hypertension; its nearest competitors (statins, ACE inhibitors, beta-blockers, diuretics, calcium channel blockers, etc.) have not been shown to be as effective. Not too many years ago, we were not aware of the existence of CoQ10, but now it is well known to exist, including in the heart.

MITOCHONDRIA/METABOLIC IMPAIRMENT

MITOCHONDRIA/METABOLIC IMPAIRMENT CoQ10 is the most nutritional/physiological treatment for hypertension; its nearest competitors (potassium, magnesium, and vitamin D3). Not too many years ago, we were not of action, and indeed many different antihypertensive actions exist, including mitochondrial. However, at this time, the mitochondrial mechanism clearly transfer in the electron transport chain, reducing free radical elaboration: not and thereby reducing the binding of nitric oxide with superoxide which is endothelial dysfunction, and the relative/absolute vasoconstriction that resultant hypertension.

from Peter H. Lar

In a personal communication by email in which the current author of the review contacted researcher Peter Langsjoen MD FACC (citations^{238,239}) about CoQ10 and endothelial dysfunction, and the relative absence of CoQ10 in the blood of patients with resultant hypertension.

Personal communication

Dear Alex,

Personal communication

Dear Alex,

In regards to the antihypertensive effect of coenzyme Q10, I do have some influence.

The first theory is that coenzyme Q10 (CoQ10) has some influence on vasodilator function because we never see a decrease in blood pressures.

My own theory on this subject is that the decrease in blood pressure that we have observed that patients with established hypertension who take CoQ10 supplementation improves their blood pressure is due to re-establish calcium ATPase activity in the cell membrane. This is a second

My own theory on this subject is that the decrease in blood pressures phenomenon. We have observed that patients with established dysfunction and it is clear that CoQ10 supplementation improves process requiring a large amount of ATP to re-establish calcium uncouple. When diastolic function improves, there is a secondary

²⁵⁶ Langsjoen P, Langsjoen P, Willems

- Multivitamin/multimineral supplementation, 600
- Muscle strength – grading scale, 24
- Musculoskeletal emergencies, 119
- Musculoskeletal Manipulation, 278
- Mycoplasma species including pneumoniae, fermentans, hominis, penetrans, genitalium, 94
- Mycoplasma species, 918
- Myelopathy, 2, 120
- Myofascial trigger points - clinical management, 274
- Myrrh, 533
- NAC, 580
- N-acetyl-cysteine (NAC), 580
- NADH-cytochrome-c-reductase, 890
- NADH-dehydrogenase, 890
- Nail pitting, 1039
- National Heart, Lung, and Blood Institute (NHLBI), 818
- Nattokinase, 781
- Naturopathic model of illness and healing, 129, 130
- Neisseria gonorrhoeae, 427
- Neoantigens/neoautoantigens, 428
- Neomycin, 964
- Neurogenic hypertension, 738
- Neurologic deficit in the evaluation of head pain - clinical management, 877
- Neurologic examination, 19, 744
- Neuronal autoimmunity, 94
- Neuropsychiatric lupus is a medical emergency, 1061
- Neuropsychiatric lupus, 119
- Neurotoxic dysbiosis, 483
- NF-kappaB, 417, 418, 419
- NFkB and its phytonutritional modulation, 376
- NFkB inhibition as an antiviral antireplication strategy, 578
- Niacinamide, 270
- NLRP3 inflammasome is activated in fibromyalgia, 419
- NLRP3 inflammasome is activated in fibromyalgia, 969
- NMDA receptor, 442, 935
- NMDA-type glutamate receptor (NMDAr), 871
- NOD-like receptors (NLR), 419
- Nonsteroidal anti-inflammatory drugs, 739
- Nuclear transcription factor kappa beta, 376, 419
- Nucleotide-binding oligomerization domain, 419
- Nucleotides, 590
- Nutrigenomics, 217
- Nutrition and Physical Degeneration, textbook by Weston Price, 206
- Nutritional Genomics, 217
- Nutritional immunomodulation, 307, 609
- Nystatin, 496, 723
- O'Keefe and Cordain in Mayo Clinic Proceedings, 206
- Obesity, 204, 822
- Objective means for the identification of allergens, 999
- Occult infections, 918
- Octreotide, 1083
- Oculomotor, 23
- Oil pulling/swishing, 505
- Olfactory, 23
- Omega-3 fatty acids - review, 359
- Ophthalmic, 23
- Opioid epidemic, 245
- Oral contraceptives, 735
- Oregano oil, 533, 720
- Organic foods rather than industrially-produced foods, 212
- Orodonal dysbiosis, 88, 503
- Orthoendocrinology, 688
- Orthomolecular Immunomodulation, 386, 993
- Orthomolecular Medicine - overview, 216
- Orthopedic/musculoskeletal examination: concepts and goals, 20
- Orwellian newspeak, 249
- Osteochondritis dissecans, 123
- Osteomyelitis, 2, 121
- Osteopathic manipulation, 798, 973
- Osteopathic manipulative treatment for adult pneumonia, 606
- Osteopathic Medicine, 149
- Overlap syndromes, 1074
- Oxygen, for cluster headaches, 892, 970, 973
- PABA, 1088
- Pain/fatigue syndromes and SIBO, 480
- Paleo-, 758
- Paleo-Mediterranean Diet, 219, 492, 597, 756
- Pancreatic and proteolytic enzymes, 273, 594
- Papaya, 567
- PAR, 110
- Paradigms, and their reasonable alternatives, 197
- Parasitology, 102
- Parasitology, 501, 529
- Parasites, 525
- Parenchymal dysbiosis/colonization—introduction to assessment, 91
- Parenchymal/Blood Dysbiosis, 511
- Parvovirus B-19 (PvB19), 548, 561, 1054, 1085
- Pasteurian paradigm, 399
- Pathophysiologic responses, 416
- Patient (mis)education in standard medicine, 914
- Pattern recognition receptors—PRRs, 417
- P-cresol, 415
- Penicillin treatment of psoriasis, 1048
- Pentosedine, 904
- Peppermint, 494, 534
- Peppermint, 722
- Peptidoglycans and exotoxins from gram-positive bacteria, 406
- Peripheral neurogenic hypertension, 738
- Pesticide exposure, 237
- Phenolic content, 209
- Pheochromocytoma, 739
- Phlogenzym, 595
- Phospholipase-A2, 373
- Physical examination, 19, 743
- Physical exertion, 201
- Physical medicine: spinal manipulation, mobilization, 605
- Physician errors, 253
- Phytochelators, 711
- Phytochemicals, 208
- PI3K/Akt/mTOR pathway, 422
- Picrorhiza, 537
- Plasminogen activator inhibitor, 362
- Pleomorphic, "cell wall-deficient" bacteria, 408
- Political and social action, 238
- Polyarteritis nodosa, 1098
- Polymicrobial dysbiosis in scleroderma, 553
- Polymyalgia Rheumatica, 1100
- Polymyositis, 1142
- Polyphenolics and phytonutrients, 581
- Porphyria cutanea tarda, 162
- Post-isometric stretching treatment for MFTP, 276
- Potaba, 1088
- Potassium supplementation, 764
- Potassium-sparing diuretic: spironolactone, 812
- Povidone iodine, 515
- Prazosin, 813
- Pre-contemplation, 194
- Preeclampsia, 736
- Pregabalin, 912
- Preparation, 194
- Primary biliary cirrhosis, 85
- Primary sclerosing cholangitis, 85
- Primary/Genetic Hemochromatosis, 160
- Primum Non Nocere, 130
- Probiotic supplementation, 535
- Probiotics, 490, 603, 782, 962
- Progressive Systemic Sclerosis, 1074
- Proinflammatory and endocrinologic activity of adipose tissue, 205
- Pro-inflammatory foods, 255
- Prolactin, 689
- Prolotherapy, 298
- Propionic acid, 414
- Propolis, 308, 377, 389, 996
- Proprioceptive rehabilitation and retraining, 293, 300
- Proprioceptive retraining, 266
- Prostacyclin, 368
- Prostaglandin D2, 368
- Prostaglandin E-1, 367
- Prostaglandin E2, 308, 368

Prostaglandin E-3, 362
 Prostaglandin F2-alpha, 369
 Prostaglandin G2, 369
 Prostaglandin G-3, 362
 Prostaglandin H2, 369
 Prostaglandin H-3, 362
 Prostaglandin I2, 368
 Prostaglandin I-3, 362
 Prostaglandin synthase complex, 373
 Protect & prevent re-injury, 254
 Protein - calculation of daily intake, 206, 268, 328
 Proteolytic enzymes (used in the treatment of dysbiosis), 535
 Proteolytic enzymes, 273, 594
 Proteus mirabilis, 471
 PRRs, 417
 Pseudomonas aeruginosa, 94, 471
 Psoriasis, main chapter, 1038
 Psoriatic rheumatism, 1038
 Putrescine, 413, 929
 Pyridoxine lowers serum/blood glutamate levels, 886
 Pyridoxine, 288, 689, 885
 Pyruvate dehydrogenase complex, 894
 Qigong, 791, 973
 Quorum sensing, 439
 Raynaud's phenomenon in scleroderma, 1094, 1129
 Raynaud's phenomenon, 94, 1129, 1133
 Reactive arthritis, 93, 466, 1110
 Reasons to avoid the use of nonsteroidal anti-inflammatory drugs (NSAIDs), 247, 249
 Referred pain with compression, 274
 REFLEXES – grading scale, 24
 Relative rest - definition and application in basic holistic care, 254
 Renal artery (renovascular) stenosis, 740
 Renal disease survey, 743
 Renal failure, cause of death in patients with SLE, 1061
 Renal injury and failure caused by NSAIDs, 250
 Resolvins, 363
 Restless leg syndrome, 949
 Retinal vasculitis, 1062
 Review of systems, 12
 Rheumatic psoriasis, 1038
 Rheumatoid Factor - interpretation, 80
 Rib manipulation, 282
 Riboflavin, 290
 Rifaximin, 496
 Rifaximin as treatment for SIBO and IBS, 954
 Rifaximin, 954, 964
 ROS: review of systems, 12
 Rosacea, 482
 Rose Bengal staining, 1121
 Roseburia intestinalis, 427
 Rosemary, 308, 377, 389, 996
 Saccharomyces boulardii, 492, 719
 SAD: Standard American Diet, 757
 S-adenosyl-methionine, 576, 962
 Safe patient + safe treatment = safe outcome, 110
 Salivary gland biopsy, 1121
 Salmonella, 93
 SAME, 576
 Sarcoidosis, 1138
 Savella, 913
 Schirmer test, 1121
 Schober test, 1114
 Scleroderma, 741
 Scleroderma secondary to xenobiotic immunotoxicity, 1074
 Scleroderma, 1074
 Screening laboratory tests in the evaluation of patients with musculoskeletal complaints, 25
 Secondary Hemochromatosis, 160
 Secretory IgA, 103, 488
 SEID, 479
 Selective estrogen receptor modulators inhibit Ebola virus infection, 572
 Selenium, 573
 Septic arthritis, 121, 125, 126
 Septic arthritis, in rheumatoid arthritis, 1023
 Seropositivity, 81, 1024
 Serotonin synthesis, 211
 Serum IgE and IgG assays, 391
 Shigella, 93
 Short-chain fatty acids, 104, 488
 SIBO, 922
 Sicca syndrome, 1120
 Sick role, 265
 Silibinin/silybin from Silymarin marianum, 593
 Silymarin, 168
 Sinorespiratory dysbiosis, 508
 Sjögren Syndrome/Disease, 550, 1120
 Skatole, 413, 929
 Skin taping to increase afferent stimuli, 296
 Skin-prick testing, 391, 999
 SLE, 1053
 Sleep apnea, 741
 Sleep, 199
 Slipped capital femoral epiphysis, 124
 Small intestinal bacterial/microbial overgrowth, 473
 Small intestine bacterial overgrowth in fibromyalgia, 923
 Social history, 13
 Sodium avoidance, 613
 Sodium benzoate, 212
 Sodium chloride, 763
 Sodium hypochlorite, 516
 Somatic dysfunction, 149
 Somatostatin analog, 1083
 Special considerations in the evaluation of children, 112
 Spinal accessory nerve, 23
 Spinal cord compression, 2, 120
 Spinal manipulation, 605
 Spironolactone, 812
 SPMD, 717
 Sporothrix schenckii, 570
 St. John's Wort, 533
 Standard Medical Treatment for Fibromyalgia, 912
 Staphylococcus aureus, 531
 Stearidonic acid, 360
 Stool analysis and comprehensive parasitology, 487
 Stool analysis, 103
 Streptococcal infections, 94
 Streptococcus pyogenes, 531
 Stress is a "whole body" phenomenon, 222
 Stress management and authentic living, 221
 Subluxation, 742
 Superantigens, 411
 Supercompensation (carbohydrates), 211
 Supplemented Paleo-Mediterranean Diet, 219, 256
 Syndemic obesity, inflammation, cardiometabolic syndrome, and brain dysfunction, 652
 Synthroid, 696
 Systemic exertion intolerance disease, 479
 Systemic Lupus Erythematosus, main chapter, 1053
 Systemic Sclerosis, 741, 1074
 Systolic hypertension, 788
 Syzygium species, 534
 Takayasu arteritis, 1098
 Tanacetum parthenium, 897
 Tartaric acid, 413, 929
 Tartrazine, 212
 Television, 191
 Temporal arteritis, 119, 1100
 Testing for Occult Infections and Dysbiosis, 86
 Testosterone, 694
 Tetanus toxoid, 427
 Tetracycline, 497
 Th17 cells, 609
 Therapeutic dependency - defined, 265
 Therapeutic exercise, 266
 Therapeutic Interventions, 956
 Therapeutic passivity - defined, 265
 Thrombocytopenia, 719
 Thromboxane A-2, 368
 Thromboxane A-3, 362
 Thromboxane B2, 368
 Thrust vectors, 279
 Thyme, 534
 Thymus vulgaris, 534
 Thyroid (insufficiency or autoimmunity), 696, 697
 Thyroid disease, 742
 Thyroid glandular—nonprescription T3, 697
 Thyroid hormone, 689
 Thyroid stimulating hormone - interpretation, 64
 Thyroid testing, 745
 Thyrolar, 697
 Tinidazole, 495

- Tissue/Parenchymal/Blood Dysbiosis, 511
 Tolle Causam, 130
 Toll-like receptors (TLR), 417
 Toll-like receptors (TLR, e.g., TLR2 and TLR4), 651
 Toll-like receptors, 418
 Total inflammatory load (TIL), 479
 Total microbial load (TML), 479, 1054
 Toxic oil syndrome, 1076
 Toxicant Exposure and Detoxification/Depuration, 705
 Toxoplasma gondii, 1086
 Tramadol, 913
 Transcendental meditation, 791
 Transgenic food avoidance, 613
 Transient synovitis, irritable hip, 123
 Treatment for MFTP, 277
 Treatment-resistant hypertension, 731
 T-regulatory cells, 609
 Tricycline, dosing and clinical use, 494, 720
 Trigeminal nerve, pain sensation in migraine, 863
 Trigeminal, 23
 Tripterygium wilfordii Hook F, 690
 Triptolide, 690
 Trochlear, 23
 Truncated self, 226
 Tryptamine, 413, 929
 Tryptophan, 960
 TSH: thyroid stimulating hormone - interpretation, 64
 Turmeric, 537
 Twitch response, 274
 Tyramine, 413, 483, 929
 Una de gato, 259
 Uncaria guianensis and Uncaria tomentosa, 259
 Undecenoic acid, 493, 720
 Undecylenic acid, 535
 Undecylenic acid, dosing and clinical use, 493, 720
 Unfolded protein response (UPR), 650
 Unhistorical, 196
 Uric acid reduction, 767
 Uric acid, 746
 Urinalysis (UA), 745
 Urinary alkalization, 770
 Urine pH, 746
 Urine sodium and potassium, 746
 Uva Ursi, 534
 Vagal stimulation, 443, 923
 Vancomycin, 964, 496
 Varicella zoster virus (VZV), 561
 Varicella zoster virus in giant cell arteritis, 552
 Varicocele, 693
 Vasculitic Diseases, 1095
 Vasculitis, 464, 508
 Vasodilators, 813
 Vegetarian diet for fibromyalgia, 958
 Vegetarian diet, 758
 Vestibulocochlear, 23
 Vinyl chloride disease, 1076
 Viruses, part 1—Known/popular "epigenomic" viruses, 1054
 Viruses, part 2—Human endogenous retroviruses (endoretroviruses, HERVs or ERVs), 1055
 Viruses, part 3—Bacteriophages of the gastrointestinal bacteria, 1059
 Viruses, part 4—Bacterial synergism via NFkB activation and immunosuppression, 1060
 Vis Medicatrix Naturae, 130
 Viscous Agents, 298
 Visual analog scale, 23
 Vitamin A for all patients with measles, 587
 Vitamin A, 587
 Vitamin A, retinoic acid, RA, 615
 Vitamin B-12 in the treatment of allergy, 388
 Vitamin B-12 in the treatment of allergy, 995
 Vitamin B-6, 288
 Vitamin C (ascorbic acid), 587
 Vitamin C in the treatment of allergy, 388, 994
 Vitamin C purge, 494, 720
 Vitamin C, 273, 770
 Vitamin D - antiinflammatory benefits, 378, 450
 Vitamin D deficiency - assessment in patients with musculoskeletal pain, 26, 916
 Vitamin D status testing, 59
 Vitamin D, 728, 742, 746, 769, 770, 801, 815, 816
 Vitamin D, 982, 983
 Vitamin D3 (cholecalciferol, not ergocalciferol), 586
 Vitamin E in the treatment of allergy, 388, 994
 Vitamin E, 612
 Vitex astus-cagnus, 690
 Wall, neurophysiology researcher, 908
 Wall-less bacteria, 408
 Waterhouse, 456
 Wegener's granulomatosis, 428, 1097, 1102
 Weight optimization, 265, 791
 Wellness, 4
 Whey peptides, 773
 Whey protein isolate, 591
 Williams, Roger J, 195
 Willow bark, 258
 Wobble board, 294
 Wobenzym, 595
 WomanWithin, 224
 Work ethic, 198
 Xenobiotic Immunotoxicity, 699
 Xenobioticcs, 920
 Xerostomia, 1120
 Xifaxan, 496, 964
 Yellow dye #5, 212
 Yersinia, 93
 Yoga, 290
 Zeff, Jared N.D., 189
 Zingiber officinale, 258
 Zonulin, 404
 Zygomycosis, 570



Chapter and Introduction

Preamble

Volume 1

1. Patient Assessments, Laboratory Interpretation, Clinical Concepts, Patient Management, Practice Management and Risk Reduction: This chapter introduces/reviews/updates patient assessments, laboratory interpretation, musculoskeletal emergencies, healthcare paradigms; the common and important conditions hemochromatosis and hypothyroidism are also included in this chapter since these need to be considered on a frequent basis in clinical practice
2. Wellness Promotion & Re-Establishing the Foundation for Health: Reviewed here are diet, lifestyle, psychosocial health, and—given the pervasiveness of persistent organic pollutants and their increasingly recognized clinical importance—an introduction to environmental medicine
3. Basic Concepts and Therapeutics in (Nondrug) Musculoskeletal Care and Integrative Pain Management: Nonpharmacologic management of musculoskeletal problems is preferred over pharmacologic (e.g., NSAID, Coxib, steroid, opioid) management because of the collateral benefits, safety, and cost-effectiveness associated with manual, dietary, botanical, and nutritional treatments. A brief discussion of the current crisis in musculoskeletal medicine is provided for contextualization and emphasis of the importance of expanding clinicians' knowledge of effective nondrug treatments
4. The Major Modifiable Factors in Sustained Inflammation: Major components of the "Functional Inflammation Protocol" are reviewed here, from concepts and molecular biology to an emphasis on practical clinical applications

1) Food & Basic Nutrition

Inflammation Mastery 4th Edition is now available in digital/ebook format via major bookstores such as Amazon.com and Barnes & Noble.

2) Infections: Dysbiosis / Viral

3) Nutritional Immunomodulation

4) Dysmetabolism, Mitochondrial Dysfunction, ERS/UPR, mTOR

5) Special Considerations: Sleep, Sociopsychology, Stress, Surgery

6) Endocrine Imbalances

7) Xenobiotic Immunotoxicity

Volume 2: Chapter 5—Clinical Applications of the Functional Inflammation Protocol

1) Hypertension

2) Diabetes Mellitus

Inflammation Mastery 4th Edition is now available in digital/ebook format via major bookstores such as Amazon.com and Barnes & Noble.

3) Migraine & Headaches

4) Fibromyalgia

5) Allergic Inflammation

6) Rheumatoid Arthritis

7) Psoriasis and Psoriatic Arthritis

8) Systemic Lupus Erythematosus

9) Scleroderma & Systemic Sclerosis

10) Vasculitic Diseases

11) Spondyloarthropathies & Reactive Arthritis

12) Sjögren Syndrome/Disease

13) Raynaud's Syndrome/Phenomenon/Disorder

14) Clinical Notes on Additional Conditions: Behçet's Disease, Sarcoidosis, Dermatomyositis and Polymyositis

Index & Appendix